https://www.taxtmi.com/news?id=48748 Veeda Lifesciences invested in Mango Sciences to deploy the AI-powered QuerentTM platform to automate patient identification, improve trial design and monitoring, broaden non Caucasian representation, and enhance operational efficiency in oncology clinical trials. The announcement also discloses that the Company is proposing a public issue subject to requisite approvals and market conditions and is preparing a draft red herring prospectus with the securities regulator, explicitly stating the communication is not an offer of securities for sale in the United States and that the offering will not be registered there. en-us Tue, 08 Jul 2025 14:31:03 +0530 Tue, 08 Jul 2025 14:31:03 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=48748 Veeda Lifesciences invested in Mango Sciences to deploy the AI-powered QuerentTM platform to automate patient identification, improve trial design and monitoring, broaden non Caucasian representation, and enhance operational efficiency in oncology clinical trials. The announcement also discloses that the Company is proposing a public issue subject to requisite approvals and market conditions and is preparing a draft red herring prospectus with the securities regulator, explicitly stating the communication is not an offer of securities for sale in the United States and that the offering will not be registered there. News - Tue, 08 Jul 2025 14:31:03 +0530 https://www.taxtmi.com/news?id=48748